WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act in the Senate:
“Moving the PASTEUR Act of 2026 forward marks meaningful progress in tackling one of our most serious public health crises. Antimicrobial resistance continues to grow every day and leaves patients fighting infections with dwindling treatment options. PASTEUR takes an important step toward restoring a sustainable antimicrobial ecosystem by promoting a model that encourages the development of innovative therapies against the most dangerous pathogens while ensuring they are used judiciously. We recognize and appreciate the bipartisan leadership behind this legislation to advance a policy solution that both fosters innovation and helps guarantee patients timely access to life-saving antimicrobial treatments.”
###